Today: 1 May 2026
Netflix stock slips after hours as Goldman trims target and Warner deal battle drags on
9 January 2026
1 min read

Netflix stock slips after hours as Goldman trims target and Warner deal battle drags on

New York, January 9, 2026, 16:38 (EST) — After-hours

  • Netflix shares were off about 1.2% after the bell
  • Goldman Sachs trimmed its price target but stuck with a Neutral rating
  • Investors are watching the Warner Bros. Discovery bidding fight and Netflix’s Jan. 20 earnings

Netflix shares slipped 1.2% to $89.46 in after-hours trading Friday. During the session, the stock ranged from $88.33 to $90.68.

Goldman Sachs cut its Netflix price target to $112 from $130 and reiterated a Neutral rating, saying investors are paying more attention to possible Warner Bros. Discovery asset acquisitions than the company’s core growth.

A takeover fight has yanked Netflix into the middle of Hollywood deal chatter. Warner Bros. Discovery’s board this week turned down Paramount Skydance’s amended offer and stuck with Netflix’s $82.7 billion agreement for the studio and other assets, dismissing Paramount’s bid as a “leveraged buyout” — largely financed with borrowed money. Netflix co-CEOs Ted Sarandos and Greg Peters said the board’s call endorsed “the superior proposal.” Reuters

Paramount ratcheted up the pressure again on Thursday, insisting its all-cash $30-per-share bid is the better deal and calling the cable-network spinoff tied to the Netflix agreement “effectively worthless.” Ross Benes, a senior analyst at eMarketer, said Paramount “has a point,” adding that “fading TV networks aren’t appealing to most investors,” even if shareholders have likely already priced those assets in. Paramount’s tender offer is set to expire on January 21, though it can extend it. Reuters

Some of Warner’s biggest shareholders aren’t lining up cleanly behind either option, a split that could keep pressure on terms and timing. “A tie goes to the incumbent,” said Alex Fitch, a partner and portfolio manager at Harris Oakmark, which owned about 4% of Warner as of Sept. 30. Vanguard, State Street and BlackRock together control about 22% of Warner, and declined to comment. Reuters

For Netflix holders, churn is what shifts the trader mindset. It’s less about whether the next series hits and more about how long the company stays trapped in a regulatory and bidding grind — and what price it ultimately pays.

Netflix’s next clear catalyst is its fourth-quarter 2025 results on January 20. The company has said it will post financials and its outlook on its investor relations site. Investors will be listening for any readout on deal work, along with the usual checkpoints: subscriber trends, advertising traction and spending plans.

But the setup can go either way. A counterbid, stricter regulatory scrutiny or a longer timetable could keep the stock stuck to deal headlines, and any slip in earnings guidance wouldn’t leave much of a cushion.

Wall Street’s next checkpoints are Netflix’s January 20 report and Paramount’s January 21 tender deadline. Traders will be scanning for new filings, tweaked terms, or any regulator signals that shift the odds.

Stock Market Today

  • Shell (UK) Rated Hold by Kepler Capital Amid Mixed Analyst Views
    May 1, 2026, 2:10 AM EDT. Shell (UK) received a Hold rating from Kepler Capital analyst Bertrand Hodee, who set a €39.00 price target. Shares closed recently at p3,288.00. Hodee, a top-ranked analyst with a 17.8% average return, covers energy stocks including Shell and BP. UBS analyst Joshua Stone also rated Shell as Hold. Conversely, Barclays kept a Buy rating on the stock. Shell's latest quarterly results showed revenue of p64.85 billion and net profit of p4.18 billion, up significantly on profit from last year despite a slight revenue decline. Insider trading sentiment turned negative recently, with increased share selling by corporate insiders over the past quarter.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 2:10 AM EDT Shell (UK) Rated Hold by Kepler Capital Amid Mixed Analyst Views May 1, 2026, 2:10 AM EDT. Shell (UK) received a Hold rating from Kepler Capital analyst Bertrand Hodee, who set a €39.00 price target. Shares closed recently at p3,288.00. Hodee, a top-ranked analyst with a 17.8% average return, covers energy stocks including Shell and BP. UBS analyst Joshua Stone also rated Shell as Hold. Conversely, Barclays kept a Buy rating on the stock. Shell's latest quarterly results showed revenue of p64.85 billion and net
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Broadcom stock jumps after Mizuho lifts target to $480 as chip rally hits record highs
Previous Story

Broadcom stock jumps after Mizuho lifts target to $480 as chip rally hits record highs

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod
Next Story

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Go toTop